Irinotecan Fresenius Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is converted in the body to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I enzyme, preventing the re‑ligation of single‑strand DNA breaks during replication. This results in accumulation of DNA damage, inhibition of transcription, and ultimately triggers apoptosis of rapidly dividing cancer cells.

The dose of Irinotecan is individualized by the prescribing oncologist based on factors such as the specific cancer type, treatment regimen, patient body‑surface area, and organ function. Dosing schedules may vary, and adjustments are often made according to laboratory results and tolerability.

Safety data for Irinotecan during pregnancy and lactation are limited. It is classified as contraindicated unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the Irinotecan Fresenius Kabi product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as topotecan or anthracyclines that target other cellular mechanisms. Compared with topotecan, Irinotecan generally has a broader indication in colorectal cancer and may be used in combination with fluoropyrimidines, offering distinct efficacy and toxicity profiles that influence regimen selection.

Irinotecan injection solution should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake vigorously. Before use, allow the product to reach room temperature if required, and follow aseptic techniques for preparation and administration.

Irinotecan is administered by intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is prepared in a sterile diluent, and dosing is calculated by the treating physician. Administration is performed in a clinical setting where vital signs and infusion reactions can be monitored.

The most serious adverse events include severe neutropenia or febrile neutropenia, which can predispose to life‑threatening infections, and severe diarrhea or colitis that may cause dehydration and electrolyte imbalance. Hepatic toxicity and rare allergic reactions such as anaphylaxis are also important to monitor closely during therapy.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or any of its components, and in those with severe hepatic impairment where drug clearance is markedly reduced. Caution is also advised for individuals with pre‑existing severe bone‑marrow suppression or uncontrolled infections.